Synthesis and Antitumor Activity of 9‐Anilino, Phenylhydrazino, and Sulphonamido Analogs of 2‐ or 4‐Methoxy‐6‐nitroacridines

Synthesis of several new 9‐anilino, phenylhydrazino, and sulphonamido analogs of 2‐ or 4‐methoxy‐6‐nitroacridine derivatives is described. The prepared compounds were tested for their in vitro antitumor activity against 60 human tumor cell lines by the National Cancer Institute (NCI) and showed a potential anticancer activity. Compounds 9‐(phenylhydrazino)‐2‐methoxy‐6‐nitroacridine (8a) and 9‐(4‐chlorophenylhydrazino)‐4‐methoxy‐6‐nitroacridine (9b) exhibited a broad spectrum antitumor activity with full panel (MG‐MID) median growth inhibition (GI50), of 16.1 and 10.9 μM and total growth inhibition (TGI) of 66.7 and 37.9 μM, respectively. Meanwhile, compounds 15a and 15b showed moderate selectivity toward leukemia cell lines. As a trial to explore the mode of action of their antitumor activity, the 6‐nitroacridine analogs were evaluated for their inhibitory effect on major cell cycle control proteins cdc2 kinase and cdc25 phosphatase as possible molecular targets that may account for antimitotic potency. None of the tested compounds proved to exert their activity via this antimitotic mode of action.

[1]  C. Cordon-Cardo.  Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.

[2]  T. Chou,et al.  9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. , 1995, Journal of medicinal chemistry.

[3]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[4]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[5]  S. Kuo,et al.  Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. , 1994, Journal of medicinal chemistry.

[6]  B. Palmer,et al.  Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  L. Meijer,et al.  Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase. , 1992, Anticancer research.

[8]  V. Rialet,et al.  A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates. , 1991, Anticancer research.

[9]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[10]  W. Denny,et al.  Redox chemistry of the 9-anilinoacridine class of antitumor agents. , 1987, Journal of medicinal chemistry.

[11]  W. Denny,et al.  Reductive metabolism and hypoxia-selective toxicity of nitracrine. , 1986, International journal of radiation oncology, biology, physics.

[12]  W. Denny,et al.  Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. , 1986, Journal of medicinal chemistry.

[13]  K. Pawlak,et al.  Cytotoxic and antitumor activity of 1-nitroacridines as an aftereffect of their interstrand DNA cross-linking. , 1984, Cancer research.

[14]  S. Crooke,et al.  Deoxyribonucleic acid breaks produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and copper. , 1984, Biochemistry.

[15]  T. Brown,et al.  Induction of limited DNA damage by the antitumor agent Cain's acridine. , 1978, Cancer research.

[16]  D. Patel.  Mutagen–nucleic acid complexes at the polynucleotide duplex level in solution: Intercalation of proflavine into poly(dA‐dT) and the melting transition of the complex , 1977, Biopolymers.

[17]  Parker Fs,et al.  The interreaction of chloroquine with the albumin of bovine plasma. , 1952 .

[18]  Kenneth D. Paull,et al.  Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen , 1992 .

[19]  W. Denny,et al.  Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. , 1989, Journal of medicinal chemistry.

[20]  W. Denny,et al.  Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine. , 1989, Journal of medicinal chemistry.

[21]  W. Dobryszycka,et al.  Blood serum peptidases in patients with ovarian carcinoma treated with Ledakrin. , 1977, Archivum immunologiae et therapiae experimentalis.